ZEEL outlines ambitious plans to expand ZEE5, pursue strategic acquisitions and bolster content
Zee Entertainment Enterprises Ltd (ZEEL) has unveiled a roadmap to further strengthen its OTT platform ZEE5, with a focus on expanding regional and international presence, enhancing original content, and exploring new segments.
The company plans to launch seven new language channels on ZEE5 and increase its original content offerings by nearly threefold as part of its aggressive growth strategy. ZEEL also aims to improve its average revenue per user (ARPU) and expects the platform to reach break-even soon.
In addition to content investments, ZEEL is eyeing strategic acquisitions, particularly in sports, gaming, and international markets, to diversify its portfolio and strengthen its foothold in the entertainment ecosystem.
The company also intends to expand into emerging experiential entertainment, immersive content, and edutainment, signaling its commitment to innovation in user experience.
ZEEL reaffirmed its focus on regional and international content to maintain its leadership in both domestic and global markets.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
8 hours ago
- Business Upturn
Prime Focus to raise Rs 5,552 crore via preferential issue, acquire additional stake in DNEG
By Aditya Bhagchandani Published on July 3, 2025, 22:38 IST Prime Focus Limited announced on July 3, 2025, that its Board of Directors has approved raising up to ₹5,552 crore through a preferential allotment of equity shares and acquiring a larger stake in its step-down subsidiary, DNEG S.a.r.l., Luxembourg. The company plans to issue up to 46.27 crore fully paid-up equity shares at ₹120 per share, partly as cash consideration and partly through a share swap. Specifically, approximately 43.01 crore shares will be issued in exchange for acquiring certain shares of DNEG, while about 3.25 crore shares will be issued to raise fresh capital of around ₹391 crore. After the transaction, Prime Focus's direct and indirect shareholding in DNEG will increase to about 88.28% from the current level. DNEG, engaged in visual effects, animation, and creative technologies for film, TV, and immersive content, reported revenues of USD 425.7 million for FY25. The board also approved: Alteration of the company's articles of association to grant special rights to an investor. A material related-party transaction between its subsidiary PF World Limited and promoter-group entity A2R Holdings. Enhancing investment, loan, and guarantee limits under Section 186 of the Companies Act. Convening an extraordinary general meeting on July 26, 2025, to seek shareholder approvals. Sixteen investors—including A2R Holdings, Novator Capital, Ranbir Kapoor, and others—will participate in the preferential allotment. A2R Holdings, the promoter group entity, will see its stake increase to about 53.46% post-issue. This move further consolidates Prime Focus's control over DNEG and strengthens its financial position to fund growth initiatives in the visual effects and creative industries globally. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
8 hours ago
- Business Upturn
India Cements announces sale of equity stake in Indonesian associate company
By Aditya Bhagchandani Published on July 3, 2025, 22:34 IST The India Cements Limited, a subsidiary of UltraTech Cement Limited, announced on July 3, 2025, that its wholly owned subsidiary PT Adcoal Energindo, Indonesia, has entered into a Share Sale and Purchase Agreement to sell its entire equity investment in its Indonesian associate PT Mitra Setia Tanah Bumbu. Upon completion of the transaction, PT Mitra Setia Tanah Bumbu will cease to be an associate of India Cements. The agreement was signed on July 3, 2025, and the sale is expected to be completed within six months. According to the company's disclosure to stock exchanges: The proposed sale consideration is Indonesian Rupiah 2,695,000,000 . Buyers of the stake are Mr. Finsa Noorcahyo F and Mr. Hari Sutikno , both Indonesian citizens. The buyers are not part of the promoter group or related parties. The associate contributed a turnover of ₹93.23 crore in the last financial year, with a net worth of ₹80.74 crore, accounting for about 1.46% of India Cements' net worth as of December 31, 2024. India Cements clarified that the transaction does not constitute a related party transaction and does not fall within a scheme of arrangement or slump sale. The company requested stock exchanges to take the disclosure on record, reiterating its commitment to compliance and transparent disclosures. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
8 hours ago
- Business Upturn
Godavari Biorefineries secures European patent for novel anti-cancer molecule
By Aditya Bhagchandani Published on July 3, 2025, 22:23 IST Godavari Biorefineries Ltd announced on July 3, 2025, that it has been granted a patent in Europe for its novel anti-cancer molecule. The patent, which covers a highly potent compound with proven efficacy on cancer and cancer stem cells, is now validated in Spain, the UK, and as a Unitary Patent across Europe. The company stated that the patent falls under the 'Anti-Cancer Research Segment', emphasizing the molecule's effectiveness in combating cancer and targeting cancer stem cells — a crucial focus area in modern oncology research. The announcement was made through a regulatory filing to the National Stock Exchange of India and BSE Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 'This patent reinforces our commitment to developing breakthrough solutions in cancer therapy, addressing one of the most challenging areas in medical science,' the company said in its communication. The company also noted that this development is part of its ongoing research and innovation efforts and is expected to contribute to its growth in the healthcare and biotech segment. For your records and information, the disclosure was signed digitally by Manoj Jain, Company Secretary and Compliance Officer at Godavari Biorefineries. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
